Fintel reports that on December 20, 2024, Stephens & Co. initiated coverage of OptimizeRx (NasdaqCM:OPRX) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 120.87% Upside
As of December 4, 2024, the average one-year price target for OptimizeRx is $10.49/share. The forecasts range from a low of $5.05 to a high of $17.85. The average price target represents an increase of 120.87% from its latest reported closing price of $4.75 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for OptimizeRx is 94MM, an increase of 6.47%. The projected annual non-GAAP EPS is 0.79.
What is the Fund Sentiment?
There are 227 funds or institutions reporting positions in OptimizeRx. This is an decrease of 4 owner(s) or 1.73% in the last quarter. Average portfolio weight of all funds dedicated to OPRX is 0.12%, an increase of 21.48%. Total shares owned by institutions decreased in the last three months by 5.54% to 14,108K shares. 
The put/call ratio of OPRX is 0.59, indicating a bullish outlook.
What are Other Shareholders Doing?
First Light Asset Management holds 1,812K shares representing 9.83% ownership of the company. In its prior filing, the firm reported owning 1,827K shares , representing a decrease of 0.85%. The firm decreased its portfolio allocation in OPRX by 27.35% over the last quarter.
AWM Investment holds 1,072K shares representing 5.82% ownership of the company. In its prior filing, the firm reported owning 1,002K shares , representing an increase of 6.48%. The firm decreased its portfolio allocation in OPRX by 12.65% over the last quarter.
Samjo Management holds 1,045K shares representing 5.67% ownership of the company. In its prior filing, the firm reported owning 780K shares , representing an increase of 25.39%. The firm increased its portfolio allocation in OPRX by 1.93% over the last quarter.
Blair William holds 677K shares representing 3.68% ownership of the company. In its prior filing, the firm reported owning 644K shares , representing an increase of 4.92%. The firm decreased its portfolio allocation in OPRX by 22.69% over the last quarter.
Rice Hall James & Associates holds 615K shares representing 3.34% ownership of the company. In its prior filing, the firm reported owning 496K shares , representing an increase of 19.39%. The firm decreased its portfolio allocation in OPRX by 13.60% over the last quarter.
OptimizeRx Background Information
(This description is provided by the company.)
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
